Neha Korde, MD | Authors

Transplant-Ineligible Multiple Myeloma: Triplet vs Quadruplet Therapy

February 08, 2022

Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.

Multiple Myeloma Precursor Disease: Current Clinical and Epidemiological Insights and Future Opportunities

June 14, 2011

In this issue of ONCOLOGY, Dr. Robert Kyle and colleagues provide their clinical and epidemiological perspective on monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM)-a perspective that is based on more than three decades of experience.